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ABSTRACT
Mumps outbreaks continue to transpire across the United States despite the available
MMR (Measles-Mumps-Rubella) vaccine and seemingly high vaccination rates. There is limited
evidence surrounding the management, impact, and prevention of mumps outbreaks. In
particular, there are currently no formal recommendations from the CDC (Centers for Disease
Control and Prevention) regarding the administration of additional doses of the MMR vaccine
during a mumps outbreak. Furthermore, there are unanswered questions of possible waning of
vaccine-induced mumps immunity and the impact of a third dose of the MMR vaccine to assist
in mumps outbreak control. Existing studies suggest that administration of the MMR vaccine
during a mumps outbreak may decrease the attack rate and number of mumps cases. This study
will characterize mumps antibody titer levels of pharmacy students obtained before and after a
university mumps outbreak. The current study will also assess for evidence of possible waning of
vaccine-induced mumps immunity in pharmacy student subjects.
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BACKGROUND
Mumps Virus
Mumps is a contagious disease caused by a Paramyxovirus, which is a member of the
Rubulavirus family. The virus replicates in the upper respiratory tract and is transmitted through
direct contact with saliva or respiratory secretions. The virus can also be transmitted via
fomites. Common modes of transmission include sneezing, coughing, talking, touch
contamination, or sharing cups and eating utensils. Once infected with the mumps virus,
patients may exhibit the common clinical manifestation of parotitis, which presents as an
inflamed jaw and cheeks.1
A person infected with the mumps virus may also experience other vague symptoms
such as fever, headache, muscle ache, loss of appetite, and tiredness. These symptoms usually
appear 16-18 days after exposure to infection but the time may range anywhere from 12-25
days. The mumps virus will generally spread before the salivary glands begin to swell, and the
spreading can continue for up to 5 days after the swelling starts.2
Measles-Mumps-Rubella (MMR) Vaccine
Mumps is a disease that has been highly preventable via the MMR vaccine that was
approved for use in the United States in 1967. Since 1989 the CDC (Centers for Disease Control
and Prevention) has recommended that children receive the first MMR vaccine dose when they
are 12-15 months old, and a second dose when they are 4-6 years old. The median efficacy of
the MMR vaccine is estimated at 78% (ranging from 49-92%) after the first dose, and 88%
(ranging from 66-95%) after the second dose.3
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Outbreaks and Studies in Recent Years
The number of mumps cases reported in the United States every year varies from
several hundred to several thousand. As depicted in Figure 1, the number of mumps cases
reported has varied significantly in recent years. According to the CDC, a mumps outbreak is
defined as three or more cases of the mumps linked by time and place.4 Despite seemingly high
vaccination coverage, mumps outbreaks continue to transpire across the United States,
particularly on college campuses. The outbreaks have occurred in all parts of the country in
highly vaccinated populations, as described in Figure 2. Several studies were completed during
these mumps outbreaks, as described in Figure 3.

2010

2011

2012

2013

2014

2015

2016

2,612
cases

370
cases

229
cases

584
cases

1,223

1,057

5,748

cases

cases

cases

Figure 1. Number of mumps cases in the United States from 2010 to 20161

2009-2010
2006
Multi-State
(mainly
Midwest)
over 6,500
cases

Orange County,
NY
2,370 cases
85% two dose
MMR vaccine
coverage6

August 2011 January 2012
California
29 cases
76% two dose
MMR vaccine
coverage7

April 2015 May 2016
University of
Illinois
317 cases
>97% two dose
MMR vaccine
coverage8

Figure 2. Recent outbreaks in the United States described with year, location, number of
cases, and percent of cases that had the recommended two doses of the MMR vaccine5

Kiley A Shelley 8
During the course of the 2006 mumps outbreaks that spread across college campuses, the
affected states worked with the American College Health Association (ACHA) and the CDC to
recommend procedures to control the outbreaks. Recommendations included that students be
required to have documentation of two MMR vaccine doses, and infected students be isolated
for 5-9 days after onset of symptoms.9 A third MMR vaccine dose was not recommended.
A study conducted at a Kansas university during the 2006 mumps outbreak concluded that
two MMR vaccine doses protect the majority of people from developing mumps.10 Two-dose
protection was evidenced by a low attack rate in the roommates of students who had developed
mumps. However, the study also concluded that two MMR vaccine doses are not effective
enough to prevent an outbreak from occurring.
The University of Illinois recommended a third MMR dose during a mumps outbreak in
2015 due to the sustained transmission and high two dose MMR vaccine coverage at the
school.8 Over a three-week period 8,200 MMR vaccine doses were administered at 5
immunization clinics. Although mumps cases declined in the following months, transmission of
the mumps virus continued until May 2016. Thus, further evaluation is needed to determine if
administering the MMR vaccine has an impact on the number of mumps cases during an
outbreak.
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When and Where Study Was Conducted
2006 – A university in Kansas

2009 – Orange County, NY Study 1

2009 – Orange County, NY Study 2

2010 – Guam

2015 – University of Illinois

Study Method and Conclusion
Evaluated 2 dose MMR protection; 2 dose
MMR protects majority of people from
developing mumps but does not prevent
outbreaks10
Administered 3rd MMR dose to families;
attack rate 0% in those that received MMR,
5.2% in those who did not, not statistically
significant6
Administered 3rd MMR dose to students
grades 6-12; attack rate 0.06% in those that
received MMR, 0.48% in those that did not,
not statistically significant11
Administered 3rd MMR dose to students age
9-14 years old; attack rate 0.9 per 1000 in
those that received MMR, 2.4 per 1000 in
those that did not, not statistically
significant12
Administered 3rd MMR dose to students and
staff; mumps cases declined but
transmission continued, further evaluation
needed8

Figure 3. Studies conducted during mumps outbreaks, the study method, and the conclusions
drawn from the study

Butler University Outbreak
In February 2016 Butler University reported a mumps outbreak. The Marion County
Public Health Department issued guidelines to manage the mumps outbreak. These guidelines
were recommendations for all individuals on campus – students, staff, and faculty – to receive a
dose of the MMR vaccine, specifically: 1) those born before 1957 were strongly advised but not
required to get a third MMR dose 2) those who were unvaccinated or unable to provide
documentation of vaccination were required to receive a first MMR dose and the second MMR
dose 28 days later 3) those who had documentation of one MMR dose were required to receive
a second MMR dose 4) those that had documentation of the recommended two MMR vaccine
doses were not directly addressed. Butler held immunization clinics in February, where over
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3,600 MMR doses were administered. The mumps outbreak was declared over in May 2016,
with a total of 24 mumps cases reported.
The mumps outbreak at Butler University generated unanswered questions: What was
the impact of administering the MMR vaccine during the mumps outbreak? Was there evidence
of waning mumps immunity in the students and/or Butler community? Could the presence of
waning mumps immunity increase the likelihood of a mumps outbreak and/or developing the
mumps infection?

NEED FOR STUDY
CDC Recommendations
The current MMR vaccination schedule recommended by the CDC and ACIP (Advisory
Committee on Immunization Practices) is to receive two doses at the ages of 12-15 months and
4-6 years old. The package insert for the MMR vaccine states that neutralizing antibodies to the
mumps virus are still detectable in most individuals 11-13 years after receiving the first MMR
vaccine dose.13 Although there is limited evidence that the neutralizing antibodies from the
MMR vaccine last longer than that time period, the CDC has not released any further
recommendations amid the mumps outbreaks across the United States.
Presently, there are no formal recommendations from the CDC regarding administration
of a third MMR vaccine dose during mumps outbreaks. The CDC does, however, provide
guidance for populations in which administration of a third MMR vaccine dose may be
considered: 1) outbreaks in people with high two-dose vaccination coverage (>90% of the
population) 2) intense exposure settings likely to facilitate transmission 3) evidence of
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sustained transmission for longer than two weeks 4) high attack rates (>5 cases per 1,000
people).4 Butler University’s outbreak meets the CDC’s criteria, as the population is highly
vaccinated, the college campus is an intense exposure setting, and there was evidence of
sustained transmission of the mumps virus for longer than two weeks. Nonetheless, additional
data on the impact and safety of the third MMR vaccine dose is needed to develop more
concrete guidelines for future outbreaks.
Existing Studies
While some studies have shown a decline in attack rates after administration of a third
MMR vaccine dose, the possibility that the declines were unrelated to the intervention could
not be excluded.11,12,14 Additionally, despite the decrease in mumps incidence demonstrated by
studies, the data is insufficient to recommend for or against the use of a third MMR vaccine
dose to assist in controlling mumps outbreaks.7 Furthermore, it is evident from continued
mumps outbreaks that the MMR vaccine does not fully protect vaccinated individuals from
developing mumps infections, but studies have shown that it can decrease the number of
mumps cases and lessen complications from the mumps virus.15 It is clear that more studies are
needed to better understand the impact of the MMR vaccine and possible waning immunity.
Current Study
The current study will provide insight into the characteristics of mumps serologic titers
observed in 2nd, 3rd, and 4th professional year pharmacy students with or without receipt of a
third MMR vaccine dose following a university outbreak. The study will also evaluate preoutbreak mumps serological titers in 3rd and 4th professional year pharmacy students to assess
the impact of time on vaccine-induced mumps antibody titers. In addition, the current study
will be continued and will assess post-outbreak mumps titers obtained from the 3rd and 4th year
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students, which may allow for the assessment of any quantitative changes that occurred in
mumps antibody titers with consideration of time and/or receipt of a third MMR vaccine dose.
If waning immunity is demonstrated among the study subjects, the data will provide evidence to
support the need to potentially adjust the health information required for matriculating
students before campus move-in. Overall, the study will add to the body of evidence
surrounding the management, impact, and prevention of mumps outbreaks.

THESIS STATEMENT
Mumps outbreaks continue to transpire across the United States. As mentioned earlier,
the CDC does not have formal recommendations regarding the administration of the MMR
vaccine during mumps outbreaks due to lack of sufficient data. However, existing studies
suggest that administration of the MMR vaccine during a mumps outbreak may decrease the
number of mumps cases.
What is the impact of the administration of a third MMR vaccine dose on the mumps
antibody titers among 2nd, 3rd, and 4th year Butler University pharmacy students? Do 3rd and 4th
year Butler University pharmacy students demonstrate evidence of waning vaccine-induced
mumps immunity?

OBJECTIVES
The primary objectives of this study are to: 1) characterize mumps antibody titers
before and after a mumps outbreak 2) determine the quantitative impact of a third dose of the
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MMR vaccine on mumps antibody titers 3) assess for evidence of waning vaccine-induced
mumps immunity.

METHODS
The current study has been approved by the Butler University IRB (Institutional Review
Board). This study consists of two parts. The first part of the study is a retrospective,
observational review of electronic health records to assess immunization and mumps titer data
for 2nd, 3rd, and 4th year pharmacy students. The second part of the study is a prospective,
longitudinal cohort study collecting data on current post-outbreak mumps antibody levels in 3rd
and 4th year students.
Study Design – Part 1: Data was collected by reviewing demographics, immunization records,
and mumps titer information in electronic health records of 2nd, 3rd, and 4th year students, as
listed in Figure 4. Per pharmacy program protocol, all students had titers obtained in their 2nd
year of pharmacy school before starting experiential rotations. All collected data was coded and
de-identified prior to being recorded on data sheets and entered into an excel spreadsheet for
data analysis.

Gender

Year of birth &
Age

Pre-outbreak
mumps titer (if
applicable) with
quantitative result

Year in
pharmacy
school

If MMR dose was
recieved during
Butler University
mumps outbreak

Housing

Post-outbreak
mumps titer (if
applicable) with
quantitative result

If there is
documentation
of receipt of 2
MMR doses

If diagnosed with
clinical mumps
infection

Figure 4. Data collected from the eligible student electronic health records at Butler University
Health Services.
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The 2nd year pharmacy students did not have a pre-outbreak titer obtained because the
outbreak occurred prior to their 2nd year of pharmacy school. The 2nd year students may have
received a third MMR vaccine dose during the Butler University mumps outbreak. In Fall 2016,
the 2nd year students had a mumps antibody titer obtained as a pharmacy program protocol.
The 2nd year student post-outbreak mumps titer data will be assessed to characterize and
quantify mumps antibody titers in those that did receive a dose of the MMR vaccine during the
outbreak vs. those that did not.
The 3rd and 4th year pharmacy students had pre-outbreak mumps antibody titers
obtained per pharmacy program protocol in Fall 2015 or Fall 2014, respectively. This data will be
assessed for evidence of waning vaccine-induced immunity to the mumps virus. The waning of
immunity is demonstrated by a negative mumps antibody titer result, 1.0 or less. The 3rd and 4th
year students may have received a third MMR vaccine dose during the Butler University mumps
outbreak.
Study Design – Part 2: The 3rd and 4th year pharmacy students have been recruited and
underwent informed consent. After consenting, the 3rd and 4th students were asked to go to the
Butler University Student Health Services clinic to undergo a standard venipuncture, which is a
collection of about 3.5 mL of blood. The blood samples obtained were sent to Mid America
Clinical Laboratory, where the specimens undergo testing for mumps virus antibodies (IgG). The
results of the assay were reported to Butler University Student Health Services in a confidential
manner and entered into the electronic health record for data collection. This data will be
assessed for quantitative changes in titer over a 1 or 2 year time period, and also for
quantitative changes following receipt of a third MMR vaccine dose, if applicable.
Inclusion Criteria – Part 1: Butler University professional phase pharmacy students in their 2nd,
3rd, or 4th year of the program, who have had their mumps antibody titers obtained per

Kiley A Shelley 15
pharmacy program protocol during the 2nd professional year of school. The potential study
subjects were identified via Butler University College of Pharmacy and Health Sciences records
according to class standing lists for the 2nd, 3rd, and 4th year pharmacy students at the time of
initiation of the study.
Inclusion Criteria – Part 2: Butler University professional phase pharmacy students in their 3rd or
4th year of the program, who were consented and had post-outbreak titers obtained at the
Butler University Student Health Services. The potential study subjects were identified via Butler
University College of Pharmacy and Health Sciences records according to class standing lists for
the 3rd and 4th year pharmacy students at the time of initiation of the study.
Proposed Statistical Analysis: Data will be analyzed using Excel. A Chi-Square test will be used to
compare categorical variables for 2nd year student data split into Groups 1 and 2. Group 1 will be
2nd year students who received a third MMR dose and demonstrated positive post-outbreak
mumps titers. Group 2 will be 2nd year students who did not receive a third MMR dose and
demonstrated positive post-outbreak mumps titers.
Data from 3rd and 4th year students will be split into Groups 3 and 4. Group 3 will consist
of 3rd and 4th year students who had positive pre-outbreak mumps titers. Group 4 will consist of
3rd and 4th year students who had negative pre-outbreak mumps titers. The Paired T-Test will
compare the mean pre and post-outbreak mumps titers of Groups 3 and 4, assessing for a
statistical difference.
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RESULTS
The 2nd year pharmacy class had a total of 112 students at the time of initiation of this
study. The class demographics include 70% (n = 78) female with an average age of 22 years old
(± 1.29). Overall, all students had documentation of receiving the two-dose MMR vaccination
series and no students were diagnosed with the mumps. During the mumps outbreak at Butler
University, 70% (n = 78) of the students received a dose of the MMR vaccine. Of the 2nd year
students that received a dose of the MMR vaccine during the mumps outbreak, 98.7% (n = 76)
had positive mumps antibody titers obtained per protocol after the outbreak. Of the students
who did not receive a dose of the MMR vaccine during the outbreak, 75.8% (n = 25)
demonstrated positive mumps antibody titers obtained per protocol after the outbreak.
The results of the pharmacy school protocol mumps antibody titers indicated that 11 of
the 112 students (9.8%) had negative titers. All 11 students received a dose of the MMR vaccine
after the negative titer resulted. Of these 11 students, 2 students had titers obtained a year
earlier in Fall 2015 and received a third MMR dose in January 2016 just prior to the mumps
outbreak. Of the remaining 9 students with negative mumps antibody titers, 8 did not receive a
third MMR dose during the Butler University mumps outbreak. However, 1 of the 9 remaining
students had received a third MMR dose during the mumps outbreak. Thus, that student had a
negative mumps antibody titer approximately 8 months after receiving a dose of the MMR
vaccine. This student received a fourth MMR dose after the negative titer result was obtained.
When quantitatively interpreting the mumps antibody titers, a value greater than 1.0 is
considered a positive titer. The average quantitative result of the mumps antibody titer in the
2nd year students was 2.88 (± 1.39). When the quantitative titer result was broken down into
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those who did vs. did not receive a third MMR dose during the outbreak, the levels were 3.14 vs.
2.38, respectively.
At the time of thesis preparation, data collection and analysis remains ongoing for the
3rd and 4th year students. Overall, all students had documentation of receiving the two-dose
MMR vaccination series prior to the outbreak and no students were diagnosed with the mumps.
Thus far, data for 97 of 4th year students has been recorded. Of these 97 students, 15.5% (n =
15) had negative titer results when their titers were obtained per pharmacy program protocol
prior to the mumps outbreak. These 15 students demonstrate evidence of waning mumps
immunity. All 15 students did receive a third MMR dose after the negative titer result was
obtained. The average quantitative level of the mumps titers in the 4th year students was 2.62 (±
1.34). During the Butler University mumps outbreak 58% (n = 56) of students received a dose of
the MMR vaccine. As data collection continues for the 3rd and 4th year students, more results will
be available regarding pre and post-outbreak titers.

DISCUSSION
As of March 25, 2017 there have been 1,965 mumps cases reported in 2017.5 Outbreaks
continue to occur across the United States, specifically on college campuses. There is currently a
lack of data to explain why these outbreaks continue to occur among populations with high twodose MMR vaccination coverage. Moreover, there are no formal recommendations from the
CDC on how to address the mumps outbreaks that continue to occur.
During the outbreak at Butler University, two immunization clinics took place and over
3,600 MMR vaccines were administered to the Butler students, staff, faculty, and community. In
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May 2016, about 3 months after the first reported cases of the mumps at Butler, the outbreak
was declared over with a total of 24 reported cases of the mumps.
Steven A. Rubin, chief of the Laboratory of Method Development at the FDA’s Center for
Biologics Evaluation and Research is studying immune responses to the MMR vaccine and its
prevention of the mumps. Outbreaks are still occurring across the United States, specifically at
college campuses. Rubin states that their “research indicates that by college age, levels of antimumps virus antibodies had declined substantially.”16 When studying college-age participants
who received a third MMR vaccine dose, Rubin and his team observed an increase in antibodies
in the first month after vaccination. However, within one year of the third MMR vaccine dose
the antibody levels dropped back down to nearly pre-third MMR dose levels. It was concluded
that a third MMR vaccine dose is unlikely to provide long-term protection, and the researchers
have now turned their efforts towards ways to improve the MMR vaccine.16
This study has aimed to characterize pharmacy student mumps antibody titer levels
before and after a university outbreak. Thus far, the findings of this study support the theory
that there is possible vaccine-induced waning immunity to the mumps virus by the time people
are college-age. This waning immunity is defined by a mumps antibody titer level of 1.0 or less.
Waning immunity was demonstrated by the 15.5% of the 4th year students that had negative
pre-outbreak mumps antibody titer results. Prior to obtaining titers, all students had
documentation of receiving the recommended two MMR vaccine doses. Thus, lack of
vaccination cannot explain the negative titer results. This data will be presented to the leaders
of the Butler University Health Services to consider possible adjustment to the policy for
incoming students regarding required immunization and/or titer documentation.
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The current study is obtaining post-outbreak mumps titer results for 3rd and 4th year
pharmacy students. Once all data has been collected, results will be able to compare
quantitative changes in mumps antibody titer over a 1 or 2 year time period. The results may
also be able to compare quantitative changes in titers in those who did vs. those who did not get
a dose of the MMR vaccine during the mumps outbreak. The results of this study will add to the
body of evidence of the studies mentioned above, regarding sustained increased mumps
antibody titer levels following receipt of a third MMR vaccine dose.
Two studies involving a third MMR vaccine dose were completed in Orange County, NY
during the 2009 mumps outbreak. The first study offered a third MMR vaccine dose to members
of a household within five days of a member of the household experiencing onset of mumps
symptoms.6 The recommendation of a third MMR dose was proposed even though the ACIP
does not advocate administration of a third MMR vaccine dose during mumps outbreaks as post
exposure prophylaxis. Of the 239 eligible people, 28 (11.7%) received a third MMR vaccine dose.
The attack rate was 0% for those who received the third MMR vaccine dose, versus a 5.2%
attack rate for those who had two MMR vaccine doses but did not receive a third dose. The
difference in the attack rates of these two groups was not statistically significant (p = 0.57).6
Although the data statistically did not demonstrate a difference in attack rates between the two
groups, the lower attack rate could be considered clinically significant. Thus, the study supports
the idea that more evidence is needed related to the management, impact, and prevention of
mumps outbreaks.
The second study completed in Orange County, NY offered third MMR vaccine doses to
students in grades 6-12, in which many of the mumps cases occurred.11 The participating schools
had to provide evidence of ongoing transmission of the mumps virus two weeks prior to the
intervention, along with documented high two-dose MMR vaccine coverage. Of the 2,178
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eligible students, 1,755 (80.6%) received a third MMR vaccine dose. The attack rate among
those who received the third MMR vaccine dose was eightfold lower (0.06% vs. 0.48%) than
those who did not, but this was not statistically significant (95% CI 0.01-1.32, p = 0.097).11 The
study concluded that the third MMR vaccine dose may limit the size and duration of an
outbreak, but the findings from the study do not support the use of a third MMR vaccine dose in
national vaccination programs.
A study completed in Guam during a mumps outbreak in 2010 administered 1,068 third
doses of the MMR vaccine to eligible students ages 9-14 at seven different schools.12 It was
found that those who received a third MMR vaccine dose had an attack rate of 0.9 per 1000,
compared to an attack rate of 2.4 per 1000 in those who had 2 or less MMR vaccine doses. This
was a 60% lower attack rate, but was not statistically significant (p = 0.67).12 Nonetheless, the
study did conclude that the administration of a third MMR vaccine dose may be effective for
controlling mumps outbreaks. This study, as well as the others mentioned above, supports the
idea that more evidence is needed related to the management, impact, and prevention of
mumps outbreaks.
A study published in 2014 assessed the magnitude and duration of aggregate mumps
virus neutralizing antibody responses after administration of a third MMR vaccine dose. The
breakdown of study subjects’ mumps virus neutralizing antibody levels over time is illustrated in
Figure 5. The study found that those who had high seropositive titers continued to possess high
seropositive titers.14 This study is significant because it indicates that a third MMR vaccine dose
could increase mumps virus neutralizing titers, which could help control outbreaks. However,
only 52.5% of the participants sustained high mumps virus titers one year after receiving the
third MMR vaccine dose. For this reason, more evidence of mumps neutralizing titers is needed
to determine the role that a third MMR vaccine dose can play in controlling mumps outbreaks.
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613 high sero (+)
baseline
all remained
sero (+) at 1
month and 1
year

38 low sero (+)
baseline

5 sero (-) baseline

1 month after
3rd MMR
vaccine dose:

1 month after 3rd MMR
vaccine dose:

9 low sero (+)

4 high sero (+)

1 low sero (+)

29 high sero (+)
1 year after 3rd
MMR vaccine
dose:*
2 sero (-)
14 low sero (+)

1 year after 3rd MMR vaccine
dose:
1 low sero (+) → sero (-)
2 high sero (+) → low sero (+)
2 remained high sero (+)

19 high sero (+)
*35 of 38 had serum drawn

Figure 5. Classification of mumps virus neutralizing antibody responses of study participants
after receiving a third MMR vaccine dose14

The current study is subject to limitations. The first part of the study is retrospective,
and therefore the data relies solely on electronic health records and data collectors to provide
accurate and sufficient documentation. In addition, the data for the first part of the study is
coming from three classes of pharmacy students, adding up to less than 500 students. This is a
small population and does not have a control group to compare to. Likewise, the second part of
the study is completely voluntary and the number of participants may vary from 15 to 200
students. Furthermore, the data has been collected from one small, private institution. This
may make any data and results difficult to generalize to a more diverse population.
Overall, the existing studies on mumps outbreaks, mumps antibody titers, and
administration of the MMR vaccine during mumps outbreaks do show a decrease in mumps
cases in those who receive the MMR vaccine during an outbreak. However, no studies thus far
have shown a statistical difference in their results.
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The outbreak at Butler University was managed similarly to other outbreaks that have
been involved in published literature. The university had a high two-dose MMR vaccination
coverage and administered the MMR vaccine at immunization clinics held during the mumps
outbreak. Approximately 12 weeks after the clinics were held, the mumps outbreak was
declared over.
The results of this study may add to the existing literature by providing additional data
on evidence of waning immunity and the impact of administering the MMR vaccine during
mumps outbreaks. The results of this study may also directly affect the Butler University campus
and community if the leaders of the Butler University Health Services consider possible
adjustment to the policy for incoming students regarding required immunization and/or titer
documentation.
The current study will continue to collect data, including the remaining electronic health
records and post-outbreak mumps antibody titers obtained for the 3rd and 4th year students.
When all necessary data has been collected and recorded, statistical analysis will be completed.
Results will be reported with applicable discussion and conclusions to accompany the data.
When this study has been completed it is anticipated that its data, results, and conclusions will
assist in developing the insufficient body of evidence surrounding the management, impact, and
prevention of mumps outbreaks.
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